These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 33096866

  • 1. Treatment of C3 Glomerulopathy in Adult Kidney Transplant Recipients: A Systematic Review.
    Gonzalez Suarez ML, Thongprayoon C, Hansrivijit P, Kovvuru K, Kanduri SR, Aeddula NR, Pivovarova AI, Chewcharat A, Bathini T, Mao MA, Basu A, Cheungpasitporn W.
    Med Sci (Basel); 2020 Oct 21; 8(4):. PubMed ID: 33096866
    [Abstract] [Full Text] [Related]

  • 2. Kidney Transplantation in C3 Glomerulopathy: A Case Series.
    Regunathan-Shenk R, Avasare RS, Ahn W, Canetta PA, Cohen DJ, Appel GB, Bomback AS.
    Am J Kidney Dis; 2019 Mar 21; 73(3):316-323. PubMed ID: 30413277
    [Abstract] [Full Text] [Related]

  • 3. Defining the complement biomarker profile of C3 glomerulopathy.
    Zhang Y, Nester CM, Martin B, Skjoedt MO, Meyer NC, Shao D, Borsa N, Palarasah Y, Smith RJ.
    Clin J Am Soc Nephrol; 2014 Nov 07; 9(11):1876-82. PubMed ID: 25341722
    [Abstract] [Full Text] [Related]

  • 4. Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis.
    Gonzalez Suarez ML, Thongprayoon C, Mao MA, Leeaphorn N, Bathini T, Cheungpasitporn W.
    J Clin Med; 2019 Jun 27; 8(7):. PubMed ID: 31252541
    [Abstract] [Full Text] [Related]

  • 5. C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First 2 Years after Transplantation.
    Tarragón B, Peleg Y, Jagannathan G, Sekulic M, Chang JH, Cohen DJ, Crew RJ, Dube GK, Fernandez HE, Husain SA, Mohan S, Morris HK, Appel GB, Jadav P, Santoriello D, Kudose S, Stokes MB, Batal I, Bomback AS.
    Clin J Am Soc Nephrol; 2024 Aug 01; 19(8):1005-1015. PubMed ID: 39116277
    [Abstract] [Full Text] [Related]

  • 6. Eculizumab and recurrent C3 glomerulonephritis.
    Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ.
    Pediatr Nephrol; 2013 Oct 01; 28(10):1975-81. PubMed ID: 23689905
    [Abstract] [Full Text] [Related]

  • 7. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
    Garg N, Zhang Y, Nicholson-Weller A, Khankin EV, Borsa NG, Meyer NC, McDermott S, Stillman IE, Rennke HG, Smith RJ, Pavlakis M.
    Nephrol Dial Transplant; 2018 Dec 01; 33(12):2260-2265. PubMed ID: 29370420
    [Abstract] [Full Text] [Related]

  • 8. Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy.
    Madden B, Singh RD, Haas M, Palma LMP, Sharma A, Vargas MJ, Gross L, Negron V, Nate T, Charlesworth MC, Theis JD, Nasr SH, Nath KA, Fervenza FC, Sethi S.
    Kidney Int; 2024 May 01; 105(5):1077-1087. PubMed ID: 38447879
    [Abstract] [Full Text] [Related]

  • 9. Poor allograft outcome in Indian patients with post-transplant C3 glomerulopathy.
    Kumar A, Ramachandran R, Rawat A, Das R, Rayat CS, Kenwar DB, Sharma A, Gupta KL, Nada R.
    Clin Kidney J; 2021 Jan 01; 14(1):291-300. PubMed ID: 33564431
    [Abstract] [Full Text] [Related]

  • 10. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
    Michels MAHM, Wijnsma KL, Kurvers RAJ, Westra D, Schreuder MF, van Wijk JAE, Bouts AHM, Gracchi V, Engels FAPT, Keijzer-Veen MG, Dorresteijn EM, Volokhina EB, van den Heuvel LPWJ, van de Kar NCAJ.
    Pediatr Nephrol; 2022 Mar 01; 37(3):601-612. PubMed ID: 34476601
    [Abstract] [Full Text] [Related]

  • 11. Eculizumab as salvage therapy for recurrent monoclonal gammopathy-induced C3 glomerulopathy in a kidney allograft.
    Moog P, Jost PJ, Büttner-Herold M.
    BMC Nephrol; 2018 May 03; 19(1):106. PubMed ID: 29724174
    [Abstract] [Full Text] [Related]

  • 12. Clinical characteristics and outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children.
    Ueda C, Horinouchi T, Inoki Y, Ichikawa Y, Tanaka Y, Kitakado H, Kondo A, Sakakibara N, Nagano C, Yamamura T, Fujimura J, Kamiyoshi N, Ishimori S, Ninchoji T, Kaito H, Shima Y, Iijima K, Nozu K, Yoshikawa N.
    Pediatr Nephrol; 2024 Sep 03; 39(9):2679-2689. PubMed ID: 38662234
    [Abstract] [Full Text] [Related]

  • 13. Rituximab fails where eculizumab restores renal function in C3nef-related DDD.
    Rousset-Rouvière C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M.
    Pediatr Nephrol; 2014 Jun 03; 29(6):1107-11. PubMed ID: 24408225
    [Abstract] [Full Text] [Related]

  • 14. Treating C3 glomerulopathy with eculizumab.
    Welte T, Arnold F, Kappes J, Seidl M, Häffner K, Bergmann C, Walz G, Neumann-Haefelin E.
    BMC Nephrol; 2018 Jan 12; 19(1):7. PubMed ID: 29329521
    [Abstract] [Full Text] [Related]

  • 15. Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series.
    Spartà G, Gaspert A, Neuhaus TJ, Weitz M, Mohebbi N, Odermatt U, Zipfel PF, Bergmann C, Laube GF.
    Clin Kidney J; 2018 Aug 12; 11(4):479-490. PubMed ID: 30094012
    [Abstract] [Full Text] [Related]

  • 16.
    Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Martín B, Smith RJH.
    ; 1993 Aug 12. PubMed ID: 20301598
    [Abstract] [Full Text] [Related]

  • 17. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
    Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, Daugas E, Decramer S, Tricot L, Cailliez M, Dubot P, Servais A, Mourey-Epron C, Pourcine F, Loirat C, Frémeaux-Bacchi V, Fakhouri F.
    Am J Kidney Dis; 2018 Jul 12; 72(1):84-92. PubMed ID: 29429752
    [Abstract] [Full Text] [Related]

  • 18. Eculizumab in post-transplant C3 glomerulonephritis caused by a C3 mutation
.
    Kim JS, Foster KW, Westphal SG.
    Clin Nephrol; 2020 Jan 12; 93(1):51-56. PubMed ID: 31661064
    [Abstract] [Full Text] [Related]

  • 19. Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis.
    Inman M, Prater G, Fatima H, Wallace E.
    Clin Kidney J; 2015 Aug 12; 8(4):445-8. PubMed ID: 26251714
    [Abstract] [Full Text] [Related]

  • 20. Outcome of C3 glomerulopathy patients: largest single-centre experience from South Asia.
    Kumar A, Nada R, Ramachandran R, Rawat A, Tiewsoh K, Das R, Rayat CS, Gupta KL, Vasishta RK.
    J Nephrol; 2020 Jun 12; 33(3):539-550. PubMed ID: 31820418
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.